Portal de Periódicos da CAPES

Linear estimates of disease progression predict survival in patients with amyotrophic lateral sclerosis

2000; Wiley; Volume: 23; Issue: 6 Linguagem: Inglês

10.1002/(sici)1097-4598(200006)23

1097-4598

Carmel Armon, Michael C. Graves, Dharmaseli Moses, Delano K. Fort�, Linda Sepulveda, Stephanie M. Darby, Richard Smith,

Parkinson's Disease Mechanisms and Treatments

Muscle & NerveVolume 23, Issue 6 p. 874-882 Research Article Linear estimates of disease progression predict survival in patients with amyotrophic lateral sclerosis Carmel Armon MD, MHS, Corresponding Author Carmel Armon MD, MHS armon@discover.net Department of Neurology Clinical Research Center, Loma Linda University School of Medicine, 11175 Campus Drive, Coleman Pavilion Room 11108, Loma Linda, California 92354, USADepartment of Neurology Clinical Research Center, Loma Linda University School of Medicine, 11175 Campus Drive, Coleman Pavilion Room 11108, Loma Linda, California 92354, USASearch for more papers by this authorMichael C. Graves MD, Michael C. Graves MD Department of Neurology, UCLA Medical Center, Los Angeles, California, USASearch for more papers by this authorDharmaseli Moses RN, Dharmaseli Moses RN Department of Neurology Clinical Research Center, Loma Linda University School of Medicine, 11175 Campus Drive, Coleman Pavilion Room 11108, Loma Linda, California 92354, USASearch for more papers by this authorDelano K. Forté, Delano K. Forté Department of Neurology, UCLA Medical Center, Los Angeles, California, USASearch for more papers by this authorLinda Sepulveda RN, PhD, Linda Sepulveda RN, PhD Department of Neurology, UCLA Medical Center, Los Angeles, California, USASearch for more papers by this authorStephanie M. Darby MS, Stephanie M. Darby MS Center for Neurologic Study, La Jolla, California, USASearch for more papers by this authorRichard A. Smith MD, Richard A. Smith MD Center for Neurologic Study, La Jolla, California, USASearch for more papers by this author Carmel Armon MD, MHS, Corresponding Author Carmel Armon MD, MHS armon@discover.net Department of Neurology Clinical Research Center, Loma Linda University School of Medicine, 11175 Campus Drive, Coleman Pavilion Room 11108, Loma Linda, California 92354, USADepartment of Neurology Clinical Research Center, Loma Linda University School of Medicine, 11175 Campus Drive, Coleman Pavilion Room 11108, Loma Linda, California 92354, USASearch for more papers by this authorMichael C. Graves MD, Michael C. Graves MD Department of Neurology, UCLA Medical Center, Los Angeles, California, USASearch for more papers by this authorDharmaseli Moses RN, Dharmaseli Moses RN Department of Neurology Clinical Research Center, Loma Linda University School of Medicine, 11175 Campus Drive, Coleman Pavilion Room 11108, Loma Linda, California 92354, USASearch for more papers by this authorDelano K. Forté, Delano K. Forté Department of Neurology, UCLA Medical Center, Los Angeles, California, USASearch for more papers by this authorLinda Sepulveda RN, PhD, Linda Sepulveda RN, PhD Department of Neurology, UCLA Medical Center, Los Angeles, California, USASearch for more papers by this authorStephanie M. Darby MS, Stephanie M. Darby MS Center for Neurologic Study, La Jolla, California, USASearch for more papers by this authorRichard A. Smith MD, Richard A. Smith MD Center for Neurologic Study, La Jolla, California, USASearch for more papers by this author First published: 23 May 2000 https://doi.org/10.1002/(SICI)1097-4598(200006)23:6 3.0.CO;2-UCitations: 48AboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onFacebookTwitterLinked InRedditWechat Abstract We have shown that linear estimates of rates of disease progression (LEP), derived from isometric myometry [grip or foot dorsiflexion (FD) strength] and forced vital capacity (FVC%), are clinically and statistically significant predictors of survival of patients with amyotrophic lateral sclerosis (ALS) from date of disease onset and, except those based on grip strength, of survival from the date of measurement. We tested these results in 2 additional groups of patients: 1) those who participated in a previously reported Protropin (GH) study; and 2) those enrolled in two other clinical trials (group 2). The LEP were derived and tested as predictors of survival. In a Cox proportional hazards model, LEP based on all measures predicted survival from disease onset in both groups of patients. Using cutoff points determined within the original group to stratify patients in the validation groups into faster and slower progressing subgroups resulted in statistically significant separation of survival curves from disease onset in group 2 for all LEP and in group 1 (the GH group) for LEP derived from FD strength; and, for survival from date of measurement in group 2, when stratified by LEP based on FD strength or FVC%. LEP based on data generated by myometry or pulmonary function studies have now been shown to predict survival in 3 unrelated groups of patients with ALS entering clinical trials. Their precise use in clinical trial design needs to be explored further. © 2000 John Wiley & Sons, Inc. Muscle Nerve 23: 874–882, 2000 Citing Literature Volume23, Issue6June 2000Pages 874-882 RelatedInformation